Literature DB >> 12499465

Immune mechanisms in chronic inflammatory demyelinating neuropathy.

Bernd C Kieseier1, Marinos C Dalakas, Hans-Peter Hartung.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated peripheral neuropathy. In recent years, the application of basic principles of general immunology has widened our understanding of the etiology and immunopathogenesis of this neuropathy. Although both cellular and humoral factors have been implicated, the data are still fragmentary and insufficient for a unified hypothesis. This review summarizes the present knowledge of the fundamental immune mechanisms related to the immunopathogenesis of CIDP and discusses the role of T cells, activated macrophages, cytokines, co-stimulatory molecules, and anti-myelin antibodies. An important factor in current approaches to the therapy of CIDP is the increasingly recognized concomitant axonal loss that occurs secondary to primary demyelination.

Entities:  

Mesh:

Year:  2002        PMID: 12499465     DOI: 10.1212/wnl.59.12_suppl_6.s7

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Inflammatory neuropathies.

Authors:  Hannah R Briemberg; Anthony A Amato
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

Review 2.  Clinical utility of peripheral nerve biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2005-02       Impact factor: 5.081

3.  t(14;18) Translocations and risk of follicular lymphoma.

Authors:  Charles S Rabkin; Carsten Hirt; Siegfried Janz; Gottfried Dölken
Journal:  J Natl Cancer Inst Monogr       Date:  2008

Review 4.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

Review 5.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

6.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

7.  Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model.

Authors:  Eroboghene E Ubogu; Nejla Yosef; Robin H Xia; Kazim A Sheikh
Journal:  J Peripher Nerv Syst       Date:  2012-03       Impact factor: 3.494

8.  Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.

Authors:  Mohamed Mahdi-Rogers; Yusuf A Rajabally
Journal:  Biologics       Date:  2010-03-24

Review 9.  The role of chemokines in Guillain-Barré syndrome.

Authors:  Sharon Chiang; Eroboghene E Ubogu
Journal:  Muscle Nerve       Date:  2013-07-27       Impact factor: 3.217

10.  Translational strategies in peripheral neuroinflammation and neurovascular repair.

Authors:  Eroboghene E Ubogu
Journal:  Transl Neurosci       Date:  2012-12-01       Impact factor: 1.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.